WhelWomen's Health Evidence Lab
WHEL-C-167 · Emerging evidence · 5/10

nonhormonal therapy for menopause

A clinical review states that nonhormonal options are among the efficacious treatments for bothersome menopausal vasomotor and GSM symptoms.

Origin · Existing drug · repurposing candidatePathway · 505(b)(2) · existing active ingredient, new indicationEvidence arm · Direct researchEvidence supports
How to read thisThe summary above and the proposed mechanism are generated by the model from the sources it ingested, and are written as the model’s reasoning rather than established fact. Any figure quoted from MATRIX is a model-derived association score, not a clinical measurement. How far the published record backs this pair is carried by the score’s own rigor dimension and traced to verbatim sources at the foot of the page.

Hypothesized mechanism

Mechanism not yet characterized in the substrate.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

How the score was reached, for this pair

The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 5 of 10 overall, a emerging reading, from a direct rated emerging in strength.

The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.

Direct research arm · anchors the headline5.0 / 10 · Emerging

Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).

Corroboration

Both claims derive from a single source, a narrative/clinical review ('Management of Menopausal Symptoms: A Review'). A single synthesis is not independent replication, and no second independent study is cited.

1 / 2

Rigor

The source is a review article but no design details (RCT, meta-analysis methodology, pooled estimates) are provided in the quotes. Without evidence of systematic methodology, this reads as a narrative review supporting only a moderate rigor score.

1 / 2

Specificity

The claims name nonhormonal options directly and reference menopausal vasomotor and GSM symptoms, so both the intervention class and the condition are explicitly identified.

2 / 2

Plausibility

The claims merely assert efficacy ('Efficacious treatments... include... nonhormonal options') without describing any mechanism by which nonhormonal therapy relieves menopausal symptoms. No mechanistic detail is provided.

0 / 2

Consistency

Both verified claims come from the same single source and point in the same positive direction, but there are no independent studies to compare. A single source defaults to a neutral consistency score.

1 / 2
How the scoring rubric works, in general

Layers not covered for this pair

Sex-specific pharmacokineticsNone on file

Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.

More on the sex-specific pharmacokinetics layer and its sources
Cycle-phase dependenceNone on file

Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.

More on the cycle-phase layer and its sources

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

  • 1Efficacious treatments for women with bothersome vasomotor symptoms or GSM symptoms include hormonal and nonhormonal options. PubMed · PMID 36749328
  • 2Efficacious treatments for women with bothersome vasomotor symptoms or GSM symptoms include hormonal and nonhormonal options. PubMed · PMID 36749328

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.

The primary sources and pipelines this evidence is drawn from